New TOYOPEARL High Resolution Ion Exchange Resins
Tosoh Bioscience expands its GigaCap family of ion exchange resins by new small particle size versions that are suited for high resolution intermediate and polishing purification steps.
New TOYOPEARL High Resolution Ion Exchange Resins
The renowned TOYOPEARL GigaCap ion exchange resins offer high binding capacities and excellent recoveries at high flow rates. They are ideally suited for high throughput purification of monoclonal antibodies and other biomolecules. Recently TOYOPEARL GigaCap DEAE was introduced to expand the choice of available functionalities by a weak anion exchange resins. Customer demands for smaller particle size versions of the existing resins initiated the development of TOYOPEARL GigaCap S-650S and Q-650S, which are now being launched.
TOYOPEARL GigaCap Q-650S is a strong anion exchange resin that combines high resolution with high binding capacity for oligonucleotide separation. TOYOPEARL GigaCap S-650S is a strong cation exchange resin and provides high resolution for better separation of process impurities and aggregates.
Tosoh Bioscience
Zettachring 6, 70567 Stuttgart, Germany
info.tbg@tosoh.comwww.tosohbioscience.de
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
